Extrapyramidal side-effects of antipsychotics in a randomised trial.

ABSTRACT:

Background

There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs.

Aims

To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia.

Method

Incidence analyses integrated data from standardised rating scales and documented use of concomitant medication or treatment discontinuation for EPS events. Mixed model analyses of change in rating scales from baseline were also conducted.

Results

There were no significant differences in incidence or change in rating scales for parkinsonism, dystonia, akathisia or tardive dyskinesia when comparing second-generation antipsychotics with perphenazine or comparing bet

SUBMITTER: Miller DD 

PROVIDER: S-EPMC2801816 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature